Medullary Thyroid Cancer Drugs Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
Medullary Thyroid Cancer Drugs Market is segemented By Therapeutic Pipeline (Phase I, Phase II, Preclinical), By Route of Administration (Oral, Subcutaneous, Intravenous, Topical), By Molecule Type (Monoclonal antibody, Small molecule, Peptide, Gene Therapy), By Product Type (Mono, Combination, Mono/Combination), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned segments.
Medullary Thyroid Cancer Drugs Market Size
Taille du Marché en USD Mn
TCAC10.6%
| Période d'Étude | 2024 - 2031 |
| Année de Base de l'Estimation | 2023 |
| TCAC | 10.6% |
| Concentration du Marché | Medium |
| Principaux Acteurs | Bayer HealthCare, TYK Medicines, Inc, Applied Pharmaceutical Science, Exelixis, Inc., Eli Lilly and Company and Among Others. |
please let us know !
Medullary Thyroid Cancer Drugs Market Analysis
The medullary thyroid cancer drugs market is estimated to be valued at USD 156 Mn in 2024 and is expected to reach USD 315 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031.
The market has been witnessing positive growth trends over the past few years. The increasing incidence of medullary thyroid cancer worldwide and rising demand for targeted therapy drugs are some of the key factors driving the market.